Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Foundayo TM, also known as orforglipron, has received approval from the FDA for chronic weight management in adults who are either obese or overweight with at least one weight-related condition. The FDA has approved Foundayo for use in conjunction with a reduced-calorie diet and increased physical activity. It is the the first non-peptide oral GLP-1 receptor agonist approved for obesity or overweight management in the United States.However, there is no confirmed approval from the EMA for this indication (1)
(1) [fda-approves-first-new-molecular-entity-under-national-priority-voucher-p…